BridgeBio (BBIO) Soars 13% on Double-Digit Price Target Upgrade

BridgeBio Pharma Inc. (NASDAQ:BBIO) is one of the 10 Stocks Investors Are Watching.

BridgeBio saw its share prices jump by 13.22 percent on Tuesday to close at $74.32 apiece, as investors took path from an investment firm’s double-digit price target upgrade for its stock.

In a market report, JPMorgan raised its price target for BridgeBio Pharma Inc. (NASDAQ:BBIO) to $94 from $89 previously, marking a 26 percent upside potential from its latest closing price. It also maintained an “overweight” rating for the stock.

Photo by Pietro Jeng on Pexels

The coverage came amid BridgeBio Pharma Inc.’s (NASDAQ:BBIO) presentation of additional data on the third phase of its clinical trial for BBP-418 in patients with limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9), at the MDA Clinical and Scientific Conference in Orlando, Florida on the same day.

According to the company, BBP-418 demonstrated a statistically significant and clinically meaningful 2.6-point improvement in North Star for Dysferlinopathy (NSAD) versus the placebo. NSAD is a clinician-reported outcome measure (ClinRO) of motor performance initially developed and designed for use in the said disease.

The company said that it was recommended by the Food and Drug Administration to pursue traditional approval for the therapy candidate.

BridgeBio Pharma Inc. (NASDAQ:BBIO) is targeting to submit a new drug application in the first half of the year, and officially launch the therapy late this year or in early 2027.

While we acknowledge the potential of BBIO as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock.

.